FDA Advisory Committee Panelists React To Plan B “Not Approvable” Letter
This article was originally published in The Tan Sheet
Executive Summary
Four current and former FDA panelists participated in May 7 interviews with "The Tan Sheet" to discuss FDA's "not approvable" letter regarding Barr Labs' OTC switch application for the Plan B (levonorgestrel) emergency contraceptive. Below are excerpts from conversations with Nonprescription Drugs Advisory Committee member Alastair Wood, MD, Vanderbilt University Medical Center; NDAC guest consultant James Trussell, PhD, Princeton University; Reproductive Health Drugs Advisory Committee member David Hager, MD, University of Kentucky; and former NDAC Chairman Randy Juhl, PhD, University of Pittsburgh.
You may also be interested in...
Reproductive Health Drugs Panel Holds On To Hager For A New Term
House members critical of FDA's "not approvable" decision on OTC emergency contraception were unsuccessful in blocking the reappointment of David Hager, MD, University of Kentucky, to the agency's Reproductive Health Drugs Advisory Committee
Reproductive Health Drugs Panel Holds On To Hager For A New Term
House members critical of FDA's "not approvable" decision on OTC emergency contraception were unsuccessful in blocking the reappointment of David Hager, MD, University of Kentucky, to the agency's Reproductive Health Drugs Advisory Committee
Reproductive Health Drugs Panel Holds On To Hager For A New Term
House members critical of FDA's "not approvable" decision on OTC emergency contraception were unsuccessful in blocking the reappointment of David Hager, MD, University of Kentucky, to the agency's Reproductive Health Drugs Advisory Committee